Fig. 4: Overall survival in patients treated with doublets vs. triplets (A) and triplets vs. 1^st generation FLT3i-based doublets vs. 2^nd generation FLT3i-based doublets (B).

A The median follow-up time was shorter in the triplet arm than in the doublet arm, 12 versus 63 months (p < 0.01), reflecting the more recent use of triplet regimens at our institution (mostly mid-2018 onwards). Patients treated with a triplet regimen (green) achieved longer median OS compared with patients treated with a doublet regimen (dark blue) (NR versus 9.5 months, P < 0.01). B The median OS in patients treated in the three groups: Triplets (green), doublets with second-generation (quizartinib or gilteritinib) FLT3 inhibitors (dark blue), and doublets with first-generation (midostaurin or sorafenib) FLT3 inhibitors (light blue) were NR, 15.7 months, and 8.7 months, respectively (P < 0.01). There was no statistically significant OS difference between patients treated with first- vs. second-generation FLT3i-based doublets (P = 0.19). LIC low intensity chemotherapy, FLT3i FLT3 inhibitor, VEN venetoclax, OS overall survival, m month, NR not reached.